The Battle Over CRISPR Could Make Or Break Some Biotech Companies
By Farai Chideya,
FiveThirtyEight
| 01. 25. 2016
[cites CGS' Marcy Darnovsky]
Untitled Document
When is $100 million not $100 million? When it’s a proxy, maybe even something akin to a bet.
The nice, round figure is the target initial public offering value for Editas Medicine, a biotechnology firm with a mission of using gene editing to treat disease. The company has already raised more than $160 million from investors, and initial evaluations of the IPO said it was almost certain to be exceeded when the stock started trading publicly.
But Editas could face a big problem. The company has hitched its fortunes to CRISPR, a revolutionary gene-editing technology embroiled in concerns over ethics and, most immediately, a patent dispute. Editas licensed the technology in 2014 from the patent holder, scientists from the Broad Institute of MIT and Harvard, as part of its research into genomic medicine, including cancer immunotherapies. But earlier this month, the U.S. Patent and Trademark Office accepted a challenge to the Broad Institute group’s patent from the University of California, which is backing a rival group of scientists. Without licensing from the eventual winner of the...
Related Articles
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...
By Elizabeth Chuck, NBC News | 07.09.2024
A Netflix docuseries has put a spotlight on the unregulated world of sperm donation, particularly the lack of stopgap measures that might prevent donors who have been banned by one country from simply going elsewhere to donate more.
Released earlier...
By Amanda Becker and Shefali Luthra, The 19th | 07.08.2024
Image by Duke University Archives from Flickr
Republicans have adopted a slate of policy positions ahead of next week’s convention that does not call for a federal legislative abortion ban, but opens the door to establishing fetal personhood.
The Republican...
By Isabelle Bartram
| 07.17.2024
Image by Kuzzat Altay from Unsplash
Uyghurs, a predominantly Muslim minority in China, are mainly located in the autonomous region of Xinjiang. The Chinese government has pursued an aggressive settlement policy in this region since 1949, with the percentage of Han Chinese in the region increasing from five to forty percent in the second half of the 20th century. Since 2014, the Uyghurs have been subject to persecution and re-education – various sources have estimated that at least one million...